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The purpose of this study was to compare hybrid capture assay with PCRs using different prim-
ers for the L1, E6-E7 regions for the detection of human papillomavirus (HPV) genome. One 
hundred twenty-five cervical smears with normal (n = 42) and abnormal (n = 83) cytology were 
investigated. Those at high-risk for HPV were studied by hybridization antibody capture assay 
and PCR with the pU-1M/pU-2R primers. Target DNA from the HPV L1 region was amplified by 
SPF10 primer set and home-PCR with MY09/MY11 primers. The presence of HPV DNA in cervi-
cal smears was detected by SPF10 (in 72% of cases), MY09/MY11 (58%), hybrid capture (55%) and 
pU-1M/pU-2R (39%). Results obtained with the SPF10 and MY09/MY11 consensus primer sets as 
well as hybrid capture and pU-1M/pU-2R specific for high-risk types differed significantly (χ2, 
P < 0.0005). The correlation between assays with the use of SPF10 and MY09/MY11 was 86% and 
between hybrid capture and the pU-1M/pU2R technique — 78%. In 49% of samples HPV DNA 
was detected by the four methods, whereas in 12% only by the SPF10 primers. The most sensi-
tive technique was found to be PCR with the use of SPF10 primers, while the most specific — 
the MY09/11 PCR method. It seems that home-PCR with MY09/MY11 primers could be applied 
in screening tests.
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INTRODUCTION
Human papillomavirus (HPV), the major cause 
of cervical cancer and cervical dysplasia,  is a mem-
ber of the Papillomaviridae family of DNA viruses. 
So far, 118 types have been identified according to 
their biological niche, oncogenic potential and phy-
logenetic position (de Villiers et al., 2004). There are 
about 40 HPV viral types that are commonly found 
in the genital tract. They are classified in the Alpha-
papillomavirus genus (Fauquet & Mayo, 2005).
 HPV’s nonenveloped capsid has an icosahe-
dral symmetry, containing 22 capsomers with a di-
ameter of 52–55 nm. The HPV virion contains circu-
lar, double-stranded DNA. The HPV genome codes 
for only eight early open reading frame proteins 
(E1-E8, with E3 and E8 function unknown) and two 
late open reading frame proteins (L1 and L2) on a 
single strand of DNA (Lowy & Howley, 2001). The 
late proteins L1 and L2 are the major and minor cap-
sid proteins of the virion. The DNA and amino-acid 
sequences are highly conserved between HPV types, 
especially of the L1 protein. The early genes of the 
HPV genome code for proteins E1 and E2 which 
are responsible for viral replication and transcrip-
tion, and E4 seems to aid virus release from infected 
cells. The E6 and E7 genes are invariably expressed 
in tumours and are sufficient to induce proliferation 
and immortalize cells in culture. Expression of E6/E7 
is required continuously to maintain the prolifera-
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tive state of the cells (zur Hausen, 2000). The protein 
products of these genes interfere with the normal 
function of tumour suppressor genes. HPV E6 inter-
acts with p53, and E7 binds to retinoblastoma pro-
tein, leading to tissue proliferation. HPV types can 
be classified according to various criteria, e.g. their 
tissue tropism, oncogenic potential and phylogenetic 
classification. 
On the basis of epidemiological studies of the 
frequencies of certain types of intraepithelial cervi-
cal lesions and cervical cancer, the anogenital HPV 
types can be generally categorized, according to 
their oncogenic potential, as being either high-risk 
or low risk (Bosch et al., 2002; Muňoz et al., 2003). 
Papillomaviruses cannot be grown in con-
ventional cell culture, and serological assays have 
only limited accuracy. As infection with HPV is fol-
lowed by a humoral immune response against the 
major capsid protein (Dillner, 1999), with antibod-
ies remaining detectable for many years, serology 
is not suitable for distinguishing present and past 
infections. Thus accurate diagnosis of HPV infection 
is based on molecular methods, including hybridi-
sation (e.g. hybrid capture, Southern and dot blot 
hybridisation) and PCR (Manos et al., 1989; Low et 
al., 1990; Cox et al., 1995; Jacobs et al., 1997; Clavel 
et al., 1999; Gravitt et al., 2000). Various PCR-based 
methods have been described for the identification 
of HPV genotypes. Individual genotypes can be de-
tected by type-specific PCR primer sets. However, 
these require the performance of multiple parallel 
assays for each sample, and type-specific PCR prim-
ers have not been reported for each HPV genotype. 
Alternatively, general PCR primer sets can be used, 
permitting simultaneous amplification of a broad 
range of HPV genotypes. Recently a novel general 
primer set, designated SPF10, amplifying a fragment 
of only 65 bp of the L1 region of the HPV genome 
was developed (Kleter et al., 1998). The aim of the 
present study was a comparison of the hybridization 
antibody capture assay versus PCRs  using different 
primer sets for the L1, E6/E7 regions for the detec-
tion of the HPV genome. The choice of these primer 
sets was determined by the fact that they are most 
commonly used in HPV detection.
MATERIALS AND METHODS 
Cervical smears were obtained from 83 wom-
en (40 ± 15 years old) with low grade (LSIL, n = 44) 
and high grade (HSIL, n = 12) squamous intraepi-
thelial lesions and cervical cancer (Ca, n = 27). All 
women were diagnosed by cytological examination. 
The diagnosis of patients with HSIL and Ca was 
also confirmed by histopathological methods. Cervi-
cal cancer patients were hospitalised in the Centre of 
Oncology, M. Sklodowska-Curie Memorial Institute 
in Krakow (Poland) and none of them had radio-
therapy before material collection.
The control group consisted of 42 women 
28 ± 5 years old undergoing preventive examina-
tions before planned pregnancy who did not display 
atypical squamous cells of the cervix. All cervical 
smears obtained before the cervical biopsy speci-
mens were taken with a cervical brush and collected 
to specimen transport medium (Digene Diagnostic, 
USA) and stored frozen at –70oC until tested. Sam-
ples were then thawed and divided into portions for 
hybridisation and PCR methods.
Hybrid capture HPV assay (Digene Diag-
nostic, USA). This test is a signal-amplified solution 
hybridisation antibody capture assay that utilizes 
chemiluminescent detection (Lorincz, 1996). Speci-
mens containing the target DNA hybridize with 
a specific HPV RNA probe cocktail. The resultant 
RNA:DNA hybrids are captured onto the surface of 
a tube coated with antibodies specific for hybrids. 
Immobilized hybrids are then reacted with alkaline 
phosphatase-conjugated antibodies specific for the 
RNA:DNA hybrids, and detected with a chemilu-
minescent substrate. The substrate is cleaved by the 
bound alkaline phosphatase. The intensity of the 
light emitted denotes the amount of target DNA 
in the specimen. In our study, the RNA probe mix 
for the detection of high-risk HPV types (HPV 16, 
18, 31, 33, 35, 45, 51, 52, 56) was used following the 
supplied instructions.
PCR. DNA was isolated using Genomic DNA 
Prep Plus kit (A&A Biotechnology, Gdynia, Poland). 
Cell samples were lysed in a buffer with proteinase 
K (1.25 mg/ml) and chaotropic salts. Addition of 
ethanol caused DNA to bind when the lysate was 
spun through a silica membrane in a microcentri-
fuge tube. Following washing to remove contami-
nants, DNA was eluted in 10 mM Tris/HCl, pH 8.5 
(preheated to 75°C). PCR was performed in a final 
reaction volume of 50 µl containing 10 µl of the iso-
lated DNA sample. 
General PCR primers (MY09/MY11, SPF10) 
to amplify a broad-spectrum of HPV genotypes and 
pU-1M/pU-2R primers to amplify high-risk HPV 
DNA were used separately. Table 1 presents the 
primers used for the PCR technique and the reaction 
conditions for each primer pair.
Each experiment was performed with separate 
positive (CaSki cells) and negative (H2O) PCR con-
trols. Analysis of the PCR products was performed 
by electrophoresis in 3% agarose gel. To ensure ad-
equate DNA preparation, PCR amplification of β-
globin gene was performed in a separate reaction, 
resulting in a 110 bp product (Saiki et al., 1985).
The analytic sensitivity of the methods used 
determined by analyses of serial dilutions of CaSki-
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cell HPV-16 DNA (Meissner, 1999) revealed that hy-
brid capture had a sensitivity limit of 50 000 HPV-16 
genomes/reaction, PCR using pU-1M/pU-2R – 300 
genomes/reaction, MY09/MY11 primers — 250 ge-
nomes/reaction, SPF10 — 10 genomes/reaction (Ca-
vuslu et al., 1996; unpublished authors’ data). The 
results were analysed by the Student’s t-test and χ2 
test.
RESULTS
HPV DNA was detected in 90 of 125 cervi-
cal smears by at least one of the following methods: 
hybrid capture and PCR with three different primers 
(pU-1M/pU-2R, MY09/MY11, SPF10). Looking at the 
results of all the methods, only SPF10/PCR showed all 
HPV positive results. HPV infection was present in 9 
(21%) women with normal cytology (control group) 
and significantly more frequently in patients with 
LSIL — 43 (98%), those with HSIL — 11 (92%) and 
with cervical cancer — 27 (100%). Results of the com-
parison of the methods used are shown in Table 2. 
Significant differences were found between 
the results of the assays performed with the four 
different methods (χ2, P<0.0005) except for the 
techniques of hybrid capture and PCR with prim-
ers MY09/MY11. SPF10 PCR was found to be the 
most sensitive and MY09/11 PCR the most spe-
cific method. The correlation between PCR with 
the universal primers MY09/MY11 and SPF10, as 
well as hybrid capture and PCR with pU-1M/pU-
2R primers specific for high-risk HPV types was 
86% and 78%, respectively. It was also demon-
strated that PCR results with the use of universal 
primers MY09/MY11 correlated in 86% with the 
hybrid capture method which detected the high-
risk types.
A positive result of HPV infection was ob-
tained in 49% of women when all four test methods 
were used. When only three test methods were used 
the positive result was obtained in 26% of women 
and for two test methods only — 13%. In 12% of ex-
amined women the infection could be detected only 
with one technique — the SPF10 PCR (Table 3).
Table 1. HPV primers used in PCR
Primers Localization  
of sequence
Product size PCR protocol PCR conditions References
MY 09
MY11
(consensus)
HPV L1 450 bp 50 mM KCl, 6.5 mM MgCl2,  
200 µM DTP, 2.5 U Taq polyme-
rase, 50 pmol of each primer
94oC/30 s
55oC/60 s
72oC/30 s
40 cycles
Manos et al., 1989
SPF10
(consensus)
HPV L1 65 bp 50 mM KCl, 10 mM Tris/HCl,  
pH 9.0, 0.1% Triton X-100,  
0.01% gelatin, 200 µM dNTP, 1.5 
U Ampli Taq Gold DNA polyme-
rase, 100 pmol of each primer
94oC/9 min
94oC/30 s
52oC/45 s
72oC/45 s
72oC/5min
40 cycles
Kleter et al., 1998
pU-1M
pU-2R
(specific for high 
risk HPV 16, 18, 
31, 33, 35, 52, 58)
HPV E6/E7 228–268 bp 50 mM KCl, 10 mM Tris/HCl, 
pH 8.3, 1.5 mM MgCl2, 200 µM 
dNTP, 2.5 U Taq polymerase,  
100 pmol of each primer
94oC/30 s
55oC/2min
72oC/2min
30 cycles
Fujinaga et al., 1991
Table 2. Comparison of positive results obtained by different methods (hybrid capture and PCRs) in women with dif-
ferent cytological diagnoses 
Detection method*
No. of  HPV-positive women with various  
cytological diagnoses No. of 
HPV(+)
Se
ns
iti
vi
ty
%
Sp
ec
ifi
ci
ty
%
χ2
 te
st
Normal LSIL HSIL Ca
SPF 10 9 43 11 27 90 100 66
P<
0.
00
05
MY09/MY11 4 34 9 25 72 80 100
HC 4 37 10 18 69 92 68
P<
0.
00
05
pU-1M/pU-2R 0 21 8 20 39 65 93
*HC, hybrid capture assay; PCR with primers: SPF10, MY09/MY11, pU-1M/pU-2R
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DISCUSSION
HPV infection is closely linked to the devel-
opment of squamous cell benign and malignant neo-
plasms of  the lower genital tract, in both men and 
women. This relationship can be estimated at many 
levels, as shown by epidemiological, clinical and mo-
lecular data. Thus, the development of methods for 
simple, rapid and accurate detection HPV has a cen-
tral role in many strategies designed to reduce the 
risk of cervical cancer. In this study we applied the 
hybrid capture test (approved by FDA for diagnostic 
use), the PCR technique with the use of commercial-
ly available primers (pU-1M/pU-2R and SPF10), and 
home-PCR with the MY09/MY11 primers. Hybrid 
capture is a simple technique that could be readily 
automated for large-scale use if required. There is 
only a slight risk of contamination and false-positive 
results, since no DNA amplification step is neces-
sary. In the hybrid capture method, a probe detect-
ing the high oncogenic potential types was applied 
so the results could be compared with the results of 
a more sensitive method, PCR with primers detect-
ing high-risk types, pU-1M/pU-2R.  This assay did 
not result in more cases of HPV infections being 
detected. In 20 women, the result obtained with the 
use of the hybrid capture technique was not con-
firmed by PCR amplification with the use of pU-1M/
pU-2R primers. A possible explanation for this could 
be that the probe used in the hybrid capture assay 
had a broader spectrum of types it could identify 
(HPV 45, 51, 56 additionally). So, the next step of 
this research was the application of universal prim-
ers for the region L1 which could detect both high 
and low oncogenic potential HPV types. The results 
of the PCR assay with the use of MY09/MY11 prim-
ers compared to the results of hybrid capture tech-
nique were found to be similar (69 and 72 patients 
HPV-positive, respectively). Other universal primers 
which detected a 65 bp fragment localized inside 
the sequence amplified by the MY09/MY11 primers, 
were also applied. The best results were obtained by 
means of this method. HPV infection was detected 
in 90 (72%) of examined women. Our previous, un-
published data suggest that SPF10 PCR is the most 
sensitive technique for HPV 16 (which occurs latent-
ly in the CaSki cell-line) detection. Therefore it may 
be suggested that this method is the most sensitive 
one also for other HPV types. The differences be-
tween the results of PCR with either MY09/MY11 or 
SPF10 primers could also be explained by the differ-
ences in the ranges of HPV types detected. Accord-
ing to other authors,  the SPF10 primer can detect 
57 different types of HPV whereas the MY09/MY11 
primers distinguish only 25 of them (Gravitt et al., 
2000; Perrons et al., 2005).
In the Perrons et al. (2002) study, HPV DNA 
was amplified from 80% of samples by SPF10 and 
from 42% only by MY09/MY11. They obtained con-
cordant positive results in 42% of samples while in 
38/100 samples only the SPF10 primer detected HPV 
DNA. In our study the results were compatible in as 
many as 80% of the samples tested (72/90). 
Comparison of the hybrid capture method 
and PCR with various primer demonstrated that in 
most cases (75%) positive results could be achieved 
by means of three or four methods.  This suggests 
that the high-risk types dominated in the examined 
tissue samples. Only in 12% of samples the posi-
tive result was obtained with the use of only one 
method, the most sensitive one detecting the broad-
est of spectrum HPV types. However, the high cost 
of HPV detection with the SPF10 PCR method lim-
its the clinical applicability of this assay in screen-
ing studies. Therefore it seems that home-PCR with 
MY09/MY11 primers, the sensitivity of which is 
comparable to the hybrid capture method, is a good 
solution for screening examinations.
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